Novo development exec: ”I’m looking at a rich pipeline across all therapy areas"

Pharmaceutical firm Novo Nordisk is heavily expanding when it comes to disease areas and technologies. The man tasked with the job looks ahead to a bright future, while not pre-emptively betting on any specific candidate.
Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR
Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

Novo Nordisk is forging a future beyond the patent expiration for its lucrative molecule semaglutide, which is behind the company’s best-selling drug by some distance, diabetes treatment Ozempic, which sold for DKK 33.7bn (USD 5.2bn) in 2021 alone.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading